DrugAnalyst Database

DRUGANALYST LTD
172 TOTTENHAM COURT RD
LONDON W1T 7NS
+44 20 3696 7500

M&A

This page lets you merge the Novo P&L with another company to see the potential impact of M&A.
Synergies are modelled by default as 10%/15%/20% of the acquisition SGA+RND costs in years 1/2/3+ starting from 2022 and taxed at Novo standalone rates. You can choose your own numbers.
Everything is modelled in USD at current FX rates.

Target Company:
Loading... {{$select.selected.name}} {{company.name}} No matches found...
Custom Synergies ($m):
2021+
2022+
2023+
2024+
2025+

This feature is only available to DRUGANALYST subscribers